D. Bron MD, PhD

P31 Approach of an IgM monoclonal gammopathy: clinical relevance of the MYD88 L265P mutation

PP39 An unusual case of paraneoplastic nephrotic syndrome in a patient with chronic lymphocytic leukemia

PP23 A simple frailty score to identify patients with malignant hemopathies who don’t benefit from standard dose chemotherapy

PP03 Amsacrine combined with high dose cytarabine in relapsed/refractory acute myeloid leukemia (rraml)

Highlights in chronic lymphocytic leukemia

SUMMARY

In previous years, the outcome of multiple phase 2 and 3 trials with oral B-cell receptor (BCR)-inhibitors in treatment-naïve and relapsed/refractory (R/R) CLL were reported. This led to the approval of these agents in the treatment of CLL. The latter resulted in a shift from intravenous chemotherapies, given for a fixed period of time to oral therapies that need to be given continuously, until progressive disease or unacceptable toxicity. Follow-up studies with these BTK inhibitors, combined with chemo-immunotherapy (CIT), with a monoclonal antibody or with the new Bcl-2 inhibitor venetoclax were presented during the 2017 annual meeting of the American Society of Hemtology (ASH). Some key messages are summarized below.

(BELG J HEMATOL 2018;9(1):22–5)

New therapeutic approaches in cutaneous T-cell lymphomas

SUMMARY

Cutaneous T-cell lymphoma is a heterogeneous group of T-cell neoplasms presenting in the skin, mycosis fungoides being the most common subtype and Sézary syndrome the leukemic form. Treatment is dependant on stage and responses to previous therapy. Treatments are divided into ‘skin-directed therapies’, which are first-line for early stage diseases, and ‘systemic therapies’ reserved for advanced stages or refractory cutaneous T-cell lymphoma. There are currently no curative therapies for cutaneous T-cell lymphoma and consecutive treatments have to be given in function of the progression of the disease. There is an urgent need for new therapies to treat symptoms, particularly pruritus and pain, and to prolong survival. This paper summarises new drugs available for cutaneous T-cell lymphoma and their mode of action. Most new drugs for cutaneous T-cell lymphoma have response rates between 30% and 50% with response durations being less than a year. New studies looking at combination or maintenance therapies may improve quality of life and disease outcome.

(BELG J HEMATOL 2017;8(3):102–6)

PP72 Transcription factors and checkpoint inhibitor expression with age: predictive markers of aging?